Are drug-eluting stents associated with a higher rate of late thrombosis than bare metal stents? Late stent thrombosis: a nuisance in both bare metal and drug-eluting stents.
about
Biodegradable polymer Biolimus-eluting stent (Nobori®) for the treatment of coronary artery lesions: review of concept and clinical resultsGlycoprotein IIb/IIIa inhibitor associated severe thrombocytopenia in patients with coronary artery disease: Clinical course and outcomes.[Coronary intervention. 2012 update].Outcomes following coronary stenting in the era of bare-metal vs the era of drug-eluting stents.Intravascular ultrasound guidance to minimize the use of iodine contrast in percutaneous coronary intervention: the MOZART (Minimizing cOntrast utiliZation With IVUS Guidance in coRonary angioplasTy) randomized controlled trialDrug-eluting stents: a review of current evidence on clinical effectiveness and late complications.Role of E2F1-cyclin E1-cyclin E2 circuit in human coronary smooth muscle cell proliferation and therapeutic potential of its downregulation by siRNAs.Reporting of harm in randomized controlled trials evaluating stents for percutaneous coronary intervention.Long-term outcomes in patients undergoing percutaneous coronary intervention with drug-eluting stents.Benefits of and safety concerns associated with drug-eluting coronary stents.Everolimus-eluting ABSORB bioresorbable vascular scaffold: present and future perspectives.Freeing the vessel from metallic cage: what can we achieve with bioresorbable vascular scaffolds?Stent thrombosis: an overview.The Supralimus sirolimus-eluting stent.Clinical performance of a novel ultrathin strut, low-dose, sirolimus-eluting stent with abluminal-only biodegradable polymeric coating for patients undergoing percutaneous coronary intervention in the daily practice.Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: from bench to clinical use.Thrombosis after stent implantation: how much of a problem is there?Metallic Limus-Eluting Stents Abluminally Coated with Biodegradable Polymers: Angiographic and Clinical Comparison of a Novel Ultra-Thin Sirolimus Stent Versus Biolimus Stent in the DESTINY Randomized Trial.Surface chemistry and polymer film thickness effects on endothelial cell adhesion and proliferation.Very late outcomes of drug-eluting stents coated with biodegradable polymers: insights from the 5-year follow-up of the randomized PAINT trial.The impact of severe distal left main disease on target lesion revascularization in patients with trifurcating coronary artery disease receiving the paclitaxel drug-eluting stent.Intermediate term outcomes with bifurcation coronary stenting using the paclitaxel drug-eluting stent: a single centre experience.One-year clinical outcome of a randomized trial of polymer-free paclitaxel-eluting stents versus biodegradable polymer-based rapamycin-eluting stents in patients with coronary heart disease.Drug-eluting stents: the continuing controversy -- a perspective on the downside of drug-eluting stents.The risks and benefits of drug-eluting stents.Optical coherence tomography findings of very late stent thrombosis after drug-eluting stent implantation.
P2860
Q26864540-70CD5A90-FC95-412A-B160-AFFD3442B977Q33397185-3FA4A6CA-DFD0-483E-8E26-09DBF09FCC50Q34180883-8E8EC469-79A9-47C6-9ED1-DA1B4A5591ABQ35878281-7EE7022F-5D33-47F9-9D2C-1D6ECE8DFE7DQ36262721-2DC8EB02-AC5B-43B0-A161-4FC847A86579Q37141941-0C701C5F-A6CB-4E2B-BAB1-7A6E7A2133BAQ37260877-31DF9F18-FD84-4A90-A833-11A10962B72AQ37469343-4AA3D5C4-EC39-4746-8222-F8C3E97727F2Q37685137-380E2A54-30D9-4739-8655-A9C97DFCE9ACQ37707419-95CB7C39-6D4B-4BD7-89F6-84EE67D3566DQ37993868-C837DBCA-8B05-4000-A98A-298432EEA88FQ38008575-4F3AD9B0-08E5-47EA-89E9-50BC779F4719Q38014978-F58CCACA-BA6A-4BD0-84AB-24C75701F192Q38099863-1E28F2E8-3D18-415F-97ED-8CA9599F63A7Q38253728-6A2609C7-952F-4AA4-B333-B33CFC630142Q38592121-87300F8C-6D5F-4FDE-99DA-656DEE19E6B5Q40097851-DD647291-70A1-46E6-A7D1-A2834C52EB7BQ40559009-4882107B-BE04-4AC5-9DEA-15CE76F973B0Q41457040-886369FD-E1C9-40A9-980C-DE988F5338C4Q41545040-578205D1-817D-4F53-8F00-DA7C943F6174Q41602116-FCF9FE51-9051-4AED-AE09-914F254703ECQ42719352-A6DD8858-E2C6-4E50-ADB7-E952882EB2F4Q44305034-CDAD4E90-EA4B-48D3-917F-2538FE8B2A33Q46753314-405AB57C-6E5D-4339-AC54-F645200B61E1Q50944377-8A8AD210-FB9A-47FE-84EB-160A71D4675AQ54438512-3E05EA47-270B-4BCB-822E-60F701F56640
P2860
Are drug-eluting stents associated with a higher rate of late thrombosis than bare metal stents? Late stent thrombosis: a nuisance in both bare metal and drug-eluting stents.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Are drug-eluting stents associ ...... metal and drug-eluting stents.
@en
type
label
Are drug-eluting stents associ ...... metal and drug-eluting stents.
@en
prefLabel
Are drug-eluting stents associ ...... metal and drug-eluting stents.
@en
P1433
P1476
Are drug-eluting stents associ ...... metal and drug-eluting stents.
@en
P2093
Joost Daemen
P304
1433-9; discussion 1439
P356
10.1161/CIRCULATIONAHA.106.666826
P407
P577
2007-03-07T00:00:00Z